Patient-specific titanium-reinforced calcium-phosphate (CaP: Ti) implants for revision cranioplasty

IF 1.9 Q3 CLINICAL NEUROLOGY
Paul Vincent Naser , Friederike Zacharias , Henrik Giese , Sandro M. Krieg , Andreas W. Unterberg , Alexander Younsi
{"title":"Patient-specific titanium-reinforced calcium-phosphate (CaP: Ti) implants for revision cranioplasty","authors":"Paul Vincent Naser ,&nbsp;Friederike Zacharias ,&nbsp;Henrik Giese ,&nbsp;Sandro M. Krieg ,&nbsp;Andreas W. Unterberg ,&nbsp;Alexander Younsi","doi":"10.1016/j.bas.2025.104213","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Cranioplasty is a common neurosurgical procedure, but infections can complicate it, necessitating revision surgery. Alloplastic patient-specific implants (PSI) are increasingly utilized, and different materials are available. This study evaluates the role of titanium-reinforced calcium-phosphate (CaP:Ti) implants in revision cranioplasty.</div></div><div><h3>Research question</h3><div>Assessing the efficacy and safety of CaP:Ti PSI in patients requiring revision cranioplasty following complications with previously failed cranioplasty attempts.</div></div><div><h3>Material and methods</h3><div>Retrospective analysis of 15 patients who underwent CaP:Ti PSI implantation for revision cranioplasty between 2016 and 2022 at a single neurosurgical department. Data on demographics, perioperative details, and outcomes were collected and assessed. Differences in distribution were assessed using Fisher's exact test, and groups were numerically compared using student's t-test. A p-value &lt;0.05 was considered statistically significant.</div></div><div><h3>Results</h3><div>In most patients, CP failure occurred early (38 days) following elective craniotomy for tumor and vascular procedures. The first revision cranioplasty was conducted in 12 cases using CaP:Ti PSI in 8 cases successfully requiring no further revision. Three cases implanted with other alloplastic materials required revision and received CaP:Ti PSI in the second (n = 2) or third (n = 1) CP attempt. The overall success rate for CaP:Ti PSI was 73.3% over more than two years of follow-up. success rate in revision cranioplasty. Surgical site complications, predominantly infections, were the main cause of CP failure. The average interval between implant removal and re-cranioplasty was 300 days. Prehabilitation using skin expanders and postoperative antibiotic use were strategies successfully utilized in this cohort.</div></div><div><h3>Discussion and conclusion</h3><div>Our findings suggest that CaP:Ti PSI implants hold promise in salvaging complicated cranioplasty in most cases despite challenges such as infection and implant failure. The use of techniques like skin expanders may contribute to better outcomes. However, further research is crucial to establish optimal timing and patient selection guidelines in revision cranioplasty using CaP:Ti implants, which could significantly impact future neurosurgical practices.</div></div>","PeriodicalId":72443,"journal":{"name":"Brain & spine","volume":"5 ","pages":"Article 104213"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain & spine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772529425000323","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Cranioplasty is a common neurosurgical procedure, but infections can complicate it, necessitating revision surgery. Alloplastic patient-specific implants (PSI) are increasingly utilized, and different materials are available. This study evaluates the role of titanium-reinforced calcium-phosphate (CaP:Ti) implants in revision cranioplasty.

Research question

Assessing the efficacy and safety of CaP:Ti PSI in patients requiring revision cranioplasty following complications with previously failed cranioplasty attempts.

Material and methods

Retrospective analysis of 15 patients who underwent CaP:Ti PSI implantation for revision cranioplasty between 2016 and 2022 at a single neurosurgical department. Data on demographics, perioperative details, and outcomes were collected and assessed. Differences in distribution were assessed using Fisher's exact test, and groups were numerically compared using student's t-test. A p-value <0.05 was considered statistically significant.

Results

In most patients, CP failure occurred early (38 days) following elective craniotomy for tumor and vascular procedures. The first revision cranioplasty was conducted in 12 cases using CaP:Ti PSI in 8 cases successfully requiring no further revision. Three cases implanted with other alloplastic materials required revision and received CaP:Ti PSI in the second (n = 2) or third (n = 1) CP attempt. The overall success rate for CaP:Ti PSI was 73.3% over more than two years of follow-up. success rate in revision cranioplasty. Surgical site complications, predominantly infections, were the main cause of CP failure. The average interval between implant removal and re-cranioplasty was 300 days. Prehabilitation using skin expanders and postoperative antibiotic use were strategies successfully utilized in this cohort.

Discussion and conclusion

Our findings suggest that CaP:Ti PSI implants hold promise in salvaging complicated cranioplasty in most cases despite challenges such as infection and implant failure. The use of techniques like skin expanders may contribute to better outcomes. However, further research is crucial to establish optimal timing and patient selection guidelines in revision cranioplasty using CaP:Ti implants, which could significantly impact future neurosurgical practices.
患者特异性钛增强磷酸钙(CaP: Ti)植入物用于翻修颅骨成形术
颅成形术是一种常见的神经外科手术,但感染会使其复杂化,需要翻修手术。同种异体患者特异性植入物(PSI)越来越多地被使用,并且有不同的材料可用。本研究评估钛增强磷酸钙(CaP:Ti)种植体在翻修颅骨成形术中的作用。研究问题:评估CaP:Ti PSI在先前颅骨成形术失败并发症后需要翻修颅骨成形术的患者中的疗效和安全性。材料与方法回顾性分析2016年至2022年在同一神经外科接受CaP:Ti PSI植入翻修颅骨成形术的15例患者。收集和评估人口统计学数据、围手术期细节和结果。使用Fisher精确检验评估分布差异,使用学生t检验对组进行数值比较。p值<;0.05被认为具有统计学意义。结果大多数患者CP衰竭发生在择期开颅手术后的早期(38天)。应用CaP:Ti PSI对12例患者进行首次翻修颅骨成形术,其中8例成功,无需进一步翻修。3例植入其他同种异体材料的病例需要翻修,并在第二次(n = 2)或第三次(n = 1) CP尝试中接受CaP:Ti PSI。在两年多的随访中,CaP:Ti PSI的总体成功率为73.3%。颅骨翻修成形术的成功率。手术部位并发症,主要是感染,是CP失败的主要原因。种植体移除和再颅骨成形术的平均间隔为300天。在这个队列中,使用皮肤扩张器和术后使用抗生素是成功的策略。讨论与结论我们的研究结果表明,尽管存在感染和种植体失败等挑战,CaP:Ti PSI种植体在大多数情况下仍有希望挽救复杂的颅骨成形术。使用像皮肤扩张器这样的技术可能会有更好的效果。然而,进一步的研究对于建立CaP:Ti植入物翻修颅骨成形术的最佳时机和患者选择指南至关重要,这可能会对未来的神经外科实践产生重大影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Brain & spine
Brain & spine Surgery
CiteScore
1.10
自引率
0.00%
发文量
0
审稿时长
71 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信